comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 07:40:06 - browse：33

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Prior authorization reform is both possible and imperative

hotspot

WSS

Immunocompromised patients offer clues on chronic Covid

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

TikTok, Instagram influencers need more rules for drug ads

A $475,000 price tag for a new cancer drug: crazy or meh?

The inclusion problem at the heart of rehabilitation research

Congressmen charge Covid hearing ‘could have been an email’

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

How to save PrEP access — and even expand it

Medicare drug price lawsuits could be good politics for Biden

What does generative AI mean for health care? We asked experts

Woodcock on FDA’s accelerated approval and her next chapter

Moonlake's readout produced a cash windfall. Risks remain

What we need to know about Arena Bioworks

Dobbs anniversary: the lost opportunity of abortion as health care

Inaction leaves children at risk from dangerous chemotherapy drug

Dobbs anniversary: the lost opportunity of abortion as health care

High breast density mammograms need follow

entertainment

Novo Nordisk to expand supply of Wegovy for U.S. patients

Do digital therapeutics have a future in medicine?

Dana Farber says 6 studies to be retracted and 31 corrected

What causes osteoarthritis? Researchers study link to brain protein

Pumping milk in bathrooms at health conferences is common

Woodcock on FDA’s accelerated approval and her next chapter

knowledge

Wikipedia

hotspot

hotspot